New drug targets Life-Threatening immune storm in rheumatic patients
NCT ID NCT07208058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a drug called plonmarlimab in 30 adults with a severe immune overreaction (macrophage activation syndrome) linked to rheumatic diseases that hasn't responded to prior treatment. Participants receive weekly IV infusions for 8 weeks. The main goal is to see if the drug can control the overactive immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Plonmarlimab (a drug given by IV injection)
What this could lead to
If it works, this could offer a new treatment option for people with severe, hard-to-treat macrophage activation syndrome, a life-threatening complication of rheumatic diseases.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY RHEUMATIC AND IMMUNOLOGIC DISEASE-ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact Email: •••••@•••••
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Henan Children's Hospital Zhengzhou Children's Hospital
RECRUITINGZhengzhou, Henan, China
Contact
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Peking University People's Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, China
Contact
-
The First Affiliated Hospital of China Medical University
WITHDRAWNShenyang, Liaoning, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, China
Contact
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact
-
The Second Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, China
Contact
-
Tianjin Medical University General Hospital
WITHDRAWNTianjin, Tianjin Municipality, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact